And if you're willing to play the game of comparing different trials then perhaps you should look at the recent Eyelea 8mg extended dosing schedule, the one the FDA knocked back.
Take a look at the published results and compare that to the Opthea phase 2 trial. Interesting.
- Forums
- ASX - By Stock
- OPT
- Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-40
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
56.0¢ |
Change
-0.005(0.88%) |
Mkt cap ! $683.2M |
Open | High | Low | Value | Volume |
57.5¢ | 57.5¢ | 55.0¢ | $544.8K | 972.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 30180 | 55.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
56.0¢ | 26694 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 30180 | 0.555 |
10 | 88484 | 0.550 |
5 | 13383 | 0.545 |
9 | 85203 | 0.540 |
5 | 200761 | 0.535 |
Price($) | Vol. | No. |
---|---|---|
0.560 | 26694 | 12 |
0.565 | 19099 | 8 |
0.570 | 35002 | 8 |
0.575 | 42000 | 5 |
0.580 | 187174 | 16 |
Last trade - 12.37pm 03/09/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |